PMID- 33466212
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 2
DP  - 2021 Jan 15
TI  - Model establishment of prognostic-related immune genes in laryngeal squamous cell 
      carcinoma.
PG  - e24263
LID - 10.1097/MD.0000000000024263 [doi]
LID - e24263
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is one of the most common 
      malignant tumors of the head and neck in the world. At present, the treatment 
      methods include surgery, radiotherapy, and chemotherapy, but the 5-year survival 
      rate is still not ideal and the quality of life of the patients is low. Due to 
      the relative lack of immunotherapy methods, this study aims to build a risk 
      prediction model of related immune genes, which can be used to effectively 
      predict the prognosis of laryngeal cancer patients, and provide targets for 
      subsequent immunotherapy. METHODS: We collected the 111 cases of laryngeal 
      squamous cell carcinoma and 12 matched normal samples in the The Cancer Genome 
      Atlas Database (TCGA) gene expression quantification database. The differentially 
      expressed related immune genes were screened by R software version 3.5.2. The COX 
      regression model of immune related genes was constructed, and the sensitivity and 
      specificity of the model were evaluated. The risk value was calculated according 
      to the model, and the risk curve was drawn to verify the correlation between 
      related immune genes, risk score, and clinical traits. RESULTS: We selected 8 
      immune-related genes that can predict the prognosis of LSCC in a COX regression 
      model and plotted the Kaplan-Meier survival curve. The 5-year survival rate of 
      the high-risk group was 16.5% (95% CI: 0.059-0.459), and that of the low-risk 
      group was 72.9% (95% CI: 0.555-0.956). The area under the receiver operating 
      characteristic (ROC) curve was used to confirm the accuracy of the model 
      (AUG = 0.887). After univariate and multivariate regression analysis, the risk 
      score can be used as an independent risk factor for predicting prognosis. The 
      risk score (P = .021) was positively correlated with the clinical Stage 
      classification. CONCLUSION: We screened out 8 immune genes related to prognosis: 
      RBP1, TLR2, AQP9, BTC, EPO, STC2, ZAP70, and PLCG1 to construct risk value 
      models, which can be used to speculate the prognosis of the disease and provide 
      new targets for future immunotherapy.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Sun, Ming
AU  - Sun M
AD  - Department of Otolaryngology, the Second Affiliated Hospital of Dalian Medical 
      University, Dalian.
FAU - Chen, Sihan
AU  - Chen S
AD  - Department of General Surgery, the First Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
FAU - Fu, Min
AU  - Fu M
AD  - Department of Otolaryngology, the Second Affiliated Hospital of Dalian Medical 
      University, Dalian.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (AQP9 protein, human)
RN  - 0 (Aquaporins)
RN  - 0 (BTC protein, human)
RN  - 0 (Betacellulin)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (EPO protein, human)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoproteins)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (RBP1 protein, human)
RN  - 0 (Retinol-Binding Proteins, Cellular)
RN  - 0 (STC2 protein, human)
RN  - 0 (TLR2 protein, human)
RN  - 0 (Toll-Like Receptor 2)
RN  - 11096-26-7 (Erythropoietin)
RN  - EC 3.1.4.11 (PLCG1 protein, human)
RN  - EC 3.1.4.3 (Phospholipase C gamma)
SB  - IM
MH  - Aquaporins/analysis
MH  - Betacellulin/analysis
MH  - Biomarkers, Tumor
MH  - Databases, Genetic
MH  - Erythropoietin/analysis
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Glycoproteins/analysis
MH  - Humans
MH  - Immunoproteins/*analysis
MH  - Intercellular Signaling Peptides and Proteins/*analysis
MH  - Laryngeal Neoplasms/*genetics/mortality
MH  - Male
MH  - Phospholipase C gamma/analysis
MH  - Prognosis
MH  - *Proportional Hazards Models
MH  - Retinol-Binding Proteins, Cellular/analysis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics/mortality
MH  - Survival Rate
MH  - Toll-Like Receptor 2/analysis
PMC - PMC7808462
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/01/21 06:00
MHDA- 2021/01/26 06:00
PMCR- 2021/01/15
CRDT- 2021/01/20 01:05
PHST- 2020/04/25 00:00 [received]
PHST- 2020/12/12 00:00 [accepted]
PHST- 2021/01/20 01:05 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2021/01/15 00:00 [pmc-release]
AID - 00005792-202101150-00095 [pii]
AID - MD-D-20-03642 [pii]
AID - 10.1097/MD.0000000000024263 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Jan 15;100(2):e24263. doi: 
      10.1097/MD.0000000000024263.